Ecopipam: Phase IIb started

Psyadon began the double-blind, crossover, U.S. Phase IIb PSY302 trial to evaluate 50 and 100 mg ecopipam once daily in about 30 patients with Tourette's syndrome ages 7-17 years. Patients will receive either ecopipam or placebo for 4 weeks and cross over to the other treatment for another 4 weeks. ...